title: Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine.
abstract: OBJECTIVE
  To determine whether active specific immunotherapy with lysates of cutaneous melanoma cells, administered with immunologic adjuvant DETOX (Ribi ImmunoChem Research, Inc, Hamilton, MT), is effective in shrinking a primary choroidal melanoma, in an elderly patient already blind in the nontumorous eye. An 81-year-old man was referred with a primary choroidal melanoma of the left eye, with virtual blindness of the right eye due to macular degeneration. He was begun on active specific immunotherapy with an experimental melanoma vaccine (melanoma theraccine) and DETOX on weeks 1, 2, 3, 4, and 6, respected after a hiatus of 2 weeks. After a response was noted, monthly injections were given.
  
  
  RESULTS
  The patient had a significant shrinkage of his choroidal melanoma from a height of 4.2 mm to 2.4 mm within 2 months. This was sustained by continual treatment for 21 months until September 1991. After the patient failed to return for 9 months while recuperating from a stroke, the lesion regrew to a height of 3.7 mm and developed an additional lobe. On resumption of monthly treatments, the lesion shrank to 3.4 mm within 3 months, lost the additional lobe, and has since remained stable. No metastases have been found over a period of nearly 4 years on quarterly computed tomographic (CT) scanning of the chest and abdomen, and magnetic resonance imaging of the head.
  
  
  CONCLUSIONS
  Active specific immunotherapy with cutaneous melanoma lysates has caused a clinically useful protracted regression of a primary choroidal melanoma in an elderly patient in whom surgery and radiation therapy were contraindicated. This may represent the first case of a primary choroidal melanoma, and perhaps the only primary tumor, successfully treated with systemic immunotherapy alone. A formal trial of active specific immunotherapy for primary choroidal melanoma in selected patients may be warranted.
authors.affiliation: School of Medicine, Department of Medicine, University of Southern California Cancer Center, Los Angeles 90033.
authors.forename: M S
authors.initials: MS
authors.lastname: Mitchell
authors.forename: P E
authors.initials: PE
authors.lastname: Liggett
authors.forename: R L
authors.initials: RL
authors.lastname: Green
authors.forename: J
authors.initials: J
authors.lastname: Kan-Mitchell
authors.forename: A L
authors.initials: AL
authors.lastname: Murphree
authors.forename: G
authors.initials: G
authors.lastname: Dean
authors.forename: L
authors.initials: L
authors.lastname: Spears
authors.forename: F
authors.initials: F
authors.lastname: Walonker
mesh_terms: D000276:Adjuvants, Immunologic; D000368:Aged; D000369:Aged, 80 and over; D002830:Choroid Neoplasms / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic